Current understanding of the rational diagnostics and treatment of acquired myasthenia gravis. Part 2: treatment
https://doi.org/10.24884/1607-4181-2016-23-3-6-11
Abstract
Due to the fact that acquired myasthenia gravis is an autoimmune disease, so rational treatment of these patients includes the symptomatic therapy (acetylcholinesterase inhibitors, potassium supplements, potassiumsaving diuretics), short-term immunotherapy (intravenous immunoglobulin, methods of extracorporeal hemocorrection), longterm immunotherapy (glucocorticosteroids, cytotoxic agents, targeted therapies), thymectomy, as well as a number of new promising therapeutic agents. The choice of effective therapy depends on identifying the clinical forms of myasthenia gravis and a complete analysis of autoimmune mechanisms underlying the disease because of similar clinical forms of myasthenia gravis may respond to similar therapies.
About the Authors
S. N. Bardakov
Military medical academy of S.M. Kirov
Russian Federation
Russian Federation
S. A. Zhivolupov
Military medical academy of S.M. Kirov
Russian Federation
Russian Federation
E. R. Barantsevich
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
M. V. Zakharov
Military medical academy of S.M. Kirov
I. N. Samartsev
Military medical academy of S.M. Kirov
References
1. Санадзе, А.Г. Применение нейромидина в лечении заболеваний периферической нервной системы / А.Г. Санадзе, Л.Ф. Касаткина, М.И. Самойлов // Атмосфера. Нервные болезни. – 2003. –№3. С. 17–18.
2. Супонева, Н.А. Внутривенная высокодозная иммунотерапия: практические рекомендации по применению в лечении дизиммунных заболеваний периферического нейромоторного аппарата / Н. А. Супонева, Д. А. Гришина // Нерв.-мышеч. болезни. – 2015. – № 4. – С. 16-23.
3. Alshekhlee, A. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals / A. Alshekhlee [et al.] // Neurology. – 2009. –№18 (72). – Р. 1548–1554.
4. Barrantes, F.J. Nongenomic effects of steroids on the nicotinic acetylcholine receptor /F.J. Barrantes [et al.] // Kidney Int. – 2000. – №4 (57). – P.1382–1389.
5. Benatar, M. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial / M. Benatar [et al.] // Ann N Y Acad Sci. – 2013. – № 1275. – Р. 17–22.
6. Bril, V. IVIg and PLEX in the treatment of myasthenia gravis / V. Bril [et al.] // Ann N Y Acad Sci. – №1275. Р. 1–6.
7. Chaudhry, V. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases / V. Chaudhry [et al.] // Neurology. – 2001. –№3 (56). – Р. 94–96.
8. Cosi, V. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study / V. Cosi [et al.] // Acta Neurol Scand. –1991. –№ 1 (84). – Р. 33–39.
9. Cruz, P.M.R. Inherited disorders of the neuromuscular junction: an update / P.M.R. Cruz, J. Palace, D. Beeson // J Neurol. – 2014. – №11 (261). – Р. 2234–2243.
10. De Feo, L.G. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis / L.G. De Feo [et al.] // Muscle Nerve. – 2002. – №1 (26). Р. 31–36.
11. Drachman, D.B. Rebooting the immune system with highdose cyclophosphamide for treatment of refractory myasthenia gravis / D.B. Drachman [et al.] // Ann N Y Acad Sci. – 2008. – №1132. – Р. 305–314.
12. Drachman, D.B. Treatment of refractory myasthenia: “rebooting” with highdose cyclophosphamide / D.B. Drachman, R.J. Jones, R.A. Brodsky // Ann Neurol. – 2003. – №1 (53). – Р. 29–34.
13. Evoli, A. Long-term results of corticosteroid therapy in patients with myasthenia gravis./ A. Evoli [et al.] // Eur Neurol. –1992. – №1 (32). – Р. 37–43.
14. Gronseth, G.S. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology / G.S. Gronseth, R.J. Barohn // Neurology. – 2000. – №1 (55). –Р. 7–15.
15. Guptill, J.T. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts / J.T. Guptill, D.B. Sanders, A. Evoli // Muscle Nerve. – 2011. – №1(44). – Р. 36–40
16. Kanda, F. Steroid Myopathy: Pathogenesis and Effects of Growth Hormone and Insulin-Like Growth Factor-I Administration / F. Kanda [et al.] // Horm Res. – 2001. – №1(56). – Р. 24–28.
17. Lauriola, L. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis / L. Lauriola [et al.] // Neurology. – 2005. – №3 (64). – Р. 536–538.
18. Leite, M.I. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG / M.I. Leite [et al.] // Ann Neurol. – 2005. – №3 (57). – Р. 444–448.
19. Pascuzzi, R.M. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients / R.M. Pascuzzi, H.B. Coslett, T.R. Johns // Ann Neurol. – 1984. – №3 (15). – Р. 291–298.
20. Ponseti, J.M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients / J.M. Ponseti [et al.] // Ann N Y Acad Sci. – 2008. – №1132. – Р. 254–263.
21. Sanders, D.B. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis /D.B. Sanders [et al.] // Neurology. – 2008. – №14 (71). – Р. 400–06.
22. Sanders, D.B. A doubleblinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of Tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis / D.B. Sanders // Neurotherapeutics. – 2015. – №2 (12). – Р. 455–460.
23. Sgirlanzoni, A. Myasthenia gravis: prolonged treatment with steroids / A. Sgirlanzoni [et al.] // Neurology. – 1984.– №2 (34). – Р. 170–174.
24. Seybold, M.E. Plasmapheresis in myasthenia gravis / M.E. Seybold // Ann N Y Acad Sci. – 1987. – №505. – Р. 584–587.
25. Takamori, M. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis / М. Takamori [et al.]// Neurology. – 2004. – №10 (62). – Р. 1894–1896.
26. Tindall, R.S. A clinical therapeutic trial of cyclosporine in myasthenia gravis / R.S. Tindall [et al.] // Ann N Y Acad Sci. – 1993. – №681. – Р. 539–551.
27. 53Witte, A.S. Azathioprine in the treatment of myasthenia gravis / A.S. Witte [et al.] // Ann Neurol. – 1984. – №6 (15). – Р. 602–605.
28. Wolfe, G.I. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy / G.I. Wolfe [et al.] // Ann N Y Acad Sci. – 2003. №998. – Р. 473–480.
29. Yeh, J.H. Double filtration plasmapheresis in myasthenia gravis—analysis of clinical efficacy and prognostic parameters / J.H. Yeh, H.C. Chiu // Acta Neurol Scand. –1999. – №5 (100). – Р. 305–309.
30. Zhou. L. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients / L. Zhou [et al.] // Muscle Nerve. – 2004. – №1 (30). – Р. 55–60.
Review
For citations:
Bardakov S.N., Zhivolupov S.A., Barantsevich E.R., Zakharov M.V., Samartsev I.N. Current understanding of the rational diagnostics and treatment of acquired myasthenia gravis. Part 2: treatment. The Scientific Notes of the Pavlov University. 2016;23(3):6-11. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-3-6-11
Views:
1120
Email this article 